382 Targeting innate immunity with BXCL701 in combination with pembrolizumab in patients with advanced solid cancers: phase 2 basket study

• Filip Janku,
• Apostolia Tsimberidou,
• Diane Healey,
• Vincent O’Neill,
• Veronica Holley,
• Abha Adat,
• Ozgur Karakuzu,
• Greg Call,
• Gabriele Urschel

Affiliations

Filip Janku

1The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Apostolia Tsimberidou

1The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Diane Healey

2Bioxcel Therapeutics, Madison, CT, USA

Vincent O’Neill

2Bioxcel Therapeutics, Madison, CT, USA

Veronica Holley

1The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Abha Adat

1The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Ozgur Karakuzu

1The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Greg Call

1The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Gabriele Urschel

1The University of Texas MD Anderson Cancer Center, Houston, TX, USA